Tecan CEO David Martyr forms new leadership team

Männedorf, Switzerland, January 30, 2013 - The Tecan Group (SIX Swiss Exchange: TECN) today announced that with the implementation of its growth strategy there will also be some changes in the leadership team. Dr. David Martyr, who became the new CEO of the Company in October 2012, is using the opportunity to reorganize and strengthen the capabilities of the leadership team.

David Martyr said: "Tecan is a very strong brand in our industry and has an excellent basis for future accelerated growth. With the expected start of the commercial supply of instruments to our partners from two major OEM programs within this year, we are preparing already for significant growth in the near future. For the mid and long-term development of our business it is essential that we have the right leadership team with extensive domain knowledge, experience and capabilities. Through this renewal process of the management team in various positions, I would like to take the opportunity to strengthen the capabilities of the leadership team in a targeted manner."

In the context of this renewal process, Dr. Bernhard Grob, who has been Head of the Partnering Business division and member of the Management Board since January 2011, will be leaving the Company. The search for a successor is underway.
Tecan's Board of Directors and CEO thank Bernhard Grob for his strong engagement and the important service of developing Tecan's Partnering Business and wish him all the best for the future.

The position of the Head of the Life Sciences division was already vacant at the entry of David Martyr. The search for a successor is in a very advanced state and an announcement of this position is expected in the near future.  

With the increased importance of business and academic partnerships, licensing as well as potential mergers and acquisitions it is also necessary for the Corporate Development department to be strengthened. The search for a Head of Corporate Development is underway.

About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN: 1210019).

For further information:

Tecan Group
Martin Braendle
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com